1369|10000|Public
25|$|Most studies {{investigating}} the effects exercise {{in patients with}} lymphedema or at risk of developing lymphedema examined patients with breast-cancer-related lymphedema. In these studies, resistance training did not increase swelling in patients with pre-existing lymphedema and decreases edema in some patients, {{in addition to other}} potential beneficial effects on cardiovascular health. Moreover, resistance training and other forms of exercise were not associated with an increased risk of developing lymphedema in patients who previously received breast cancer-related treatment. Compression garments should be worn during exercise (with the possible exception of swimming in some patients). Patients who have or risk lymphedema should consult their physician or certified lymphedema therapist before beginning an exercise regimen. Resistance training is not recommended in the immediate post-operative period in patients who have undergone <b>axillary</b> <b>lymph</b> <b>node</b> dissection for breast cancer.|$|E
2500|$|Secondary {{lymphedema}} affects {{both men}} and women. In women, it is most prevalent in the upper limbs after breast cancer surgery, in particular after <b>axillary</b> <b>lymph</b> <b>node</b> dissection, occurring in the arm {{on the side of}} the body in which the surgery is performed. Breast and trunk lymphedema can also occur but, go unrecognised as there is swelling in the area after surgery and its symptoms ( [...] peau d' orange and/or an inverted nipple [...] ) can be confused with post surgery fat necrosis. In Western countries, secondary lymphedema is most commonly due to cancer treatment. Between 38 and 89% of breast cancer patients suffer from lymphedema due to <b>axillary</b> <b>lymph</b> <b>node</b> dissection and/or radiation. Unilateral lymphedema occurs in up to 41% of patients after gynecologic cancer. For men, a 5-66% incidence of lymphedema has been reported in patients treated with incidence depending on whether staging or radical removal of lymph glands was done in addition to radiotherapy.|$|E
50|$|In 2009, he pioneered {{pre-operative}} <b>axillary</b> <b>lymph</b> <b>node</b> staging {{in breast}} cancer treatment.|$|E
50|$|Lymphadenopathy of the <b>axillary</b> <b>lymph</b> <b>nodes</b> can {{be defined}} as solid nodes {{measuring}} more than 1.5 cm without fatty hilum. <b>Axillary</b> <b>lymph</b> <b>nodes</b> may be normal up to 3 cm if consisting largely of fat.|$|R
25|$|Approximately 75% of {{the lymph}} from the breast {{travels to the}} <b>axillary</b> <b>lymph</b> <b>nodes</b> {{on the same side}} of the body, whilst 25% of the lymph travels to the parasternal nodes (beside the sternum bone). A small amount of {{remaining}} lymph travels to the other breast and to the abdominal <b>lymph</b> <b>nodes.</b> The <b>axillary</b> <b>lymph</b> <b>nodes</b> include the pectoral (chest), subscapular (under the scapula), and humeral (humerus-bone area) lymph-node groups, which drain to the central <b>axillary</b> <b>lymph</b> <b>nodes</b> and to the apical <b>axillary</b> <b>lymph</b> <b>nodes.</b> The lymphatic drainage of the breasts is especially relevant to oncology because breast cancer is common to the mammary gland, and cancer cells can metastasize (break away) from a tumour and be dispersed to other parts of the body by means of the lymphatic system.|$|R
50|$|Axillary {{lymphadenopathy}} is lymphadenopathy of the <b>axillary</b> <b>lymph</b> <b>nodes.</b>|$|R
50|$|About 75% of lymph {{from the}} breasts drains into the {{axillary}} lymph nodes, making them {{important in the}} diagnosis of breast cancer. A doctor will usually {{refer a patient to}} a surgeon to have an <b>axillary</b> <b>lymph</b> <b>node</b> dissection to see if the cancer cells have been trapped in the nodes. For clinical stages I and II breast cancer, <b>axillary</b> <b>lymph</b> <b>node</b> dissection should only be performed after first attempting sentinel node biopsy.|$|E
50|$|For {{clinical}} stages I and II breast cancer, <b>axillary</b> <b>lymph</b> <b>node</b> dissection {{should only}} be performed after first attempting sentinel node biopsy. Sentinel node biopsy can establish cancer staging of the axilla if there are positive lymph nodes present. It also is less risky than performing lymphadenectomy, having fewer side effects and a much lower chance of causing lymphedema. If cancer is not present in sentinel lymph nodes then the <b>axillary</b> <b>lymph</b> <b>node</b> dissection should not be performed.|$|E
50|$|The better-known {{examples}} of lymphadenectomy are <b>axillary</b> <b>lymph</b> <b>node</b> dissection for breast cancer; radical neck dissection for {{head and neck}} cancer and thyroid cancer; D2 lymphadenectomy for gastric cancer; and total mesorectal excision for rectal cancer.|$|E
5000|$|Five {{groups of}} <b>axillary</b> <b>lymph</b> <b>nodes</b> and the {{associated}} lymphatics ...|$|R
40|$|Triple {{negative}} {{breast cancer}} (TNBC) is breast cancer that demonstrate {{the absence of}} estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. TNBC has an aggressive behaviour, high frequency of metastasis to the <b>axillary</b> <b>lymph</b> <b>nodes</b> and recurrence, and poor prognosis. Metastasis to the <b>axillary</b> <b>lymph</b> <b>nodes</b> will affect the rate of survival and recurrence in TNBC. Melanoma cell adhession molecule (MCAM) is a membrane glycoprotein of the immunoglobulin superfamily, which {{is involved in the}} cells binding, which later became known as the marker for the progression and metastasis of melanoma and carcinoma of the prostate. However, MCAM role in mammary carcinoma still controversial. The aim {{of this study was to}} assess correlation between MCAM expression with incidence of metastatic to <b>axillary</b> <b>lymph</b> <b>nodes</b> in TNBC. This research was conducted during January 1 st 2010 –April 31 st 2015 at Pathology Anatomy, Faculty of Medicine, Universitas Padjadjaran. This study used a cross-sectional design, using lambda correlation test. MCAM immunohistochemical staining performed on 56 samples of paraffin blocks of TNBC group that did not metastasized and has metastasized to the <b>axillary</b> <b>lymph</b> <b>nodes.</b> A total of 22 of 28 (78. 6 %) of TNBC metastatic to <b>axillary</b> <b>lymph</b> <b>nodes</b> have histoskor MCAM value < 4 (negative), whereas 16 of 28 (57. 1 %) of TNBC non-metastatic have histoskor value ≥ 4 (positive). Negative expression of MCAM correlated with TNBC that had metastasized to <b>axillary</b> <b>lymph</b> <b>nodes,</b> although not the only factor that influenced them...|$|R
40|$|Cystosarcoma phyllodes are {{uncommon}} breast tumors which rarely metastasize to <b>axillary</b> <b>lymph</b> <b>nodes.</b> The tumor {{is similar}} to fibroadenoma in structure, but it is different histologically. Although surgery (excision vs. mastectomy) is the mainstay of treatment, the need for adjuvant therapies such as radiotherapy for a malignant variety is unclear. Its association with ipsilateral tubercular <b>axillary</b> <b>lymph</b> <b>nodes</b> has not been reported in literature so far. We report a 35 -year-old female that presented with a giant borderline malignant phyllodes tumor of the right breast along with ipsilateral tubercular granulomatous <b>axillary</b> <b>lymph</b> <b>nodes.</b> [Arch Clin Exp Surg 2015; 4 (2. 000) : 114 - 117...|$|R
50|$|A {{positive}} <b>axillary</b> <b>lymph</b> <b>node</b> is a {{lymph node}} {{in the area}} of the armpit (axilla) to which cancer has spread. This spread is determined by surgically removing some of the lymph nodes and examining them under a microscope to see whether cancer cells are present.|$|E
50|$|If {{cancer cells}} {{are found in}} the nodes it {{increases}} the risk of metastatic breast cancer. Another method of determining breast cancer spread is to perform an endoscopic axillary sentinel node biopsy. This involves injecting a dye into the breast lump and seeing which node it first spread to (the sentinel node). This node is then removed and examined. If there is no cancer present, it is assumed the cancer has not spread to the other lymph nodes. This procedure is often less invasive and less damaging than the <b>axillary</b> <b>lymph</b> <b>node</b> dissection. The estimated risk of lymphedema following sentinel lymph node procedure is less than 3%. The approximate risk of lymphedema following <b>axillary</b> <b>lymph</b> <b>node</b> dissection is 10-15% and this can slightly increase with the addition of radiotherapy and chemotherapy to as much as 20-25% depending on the extent of dissection, extent of radiotherapy fields, and history of chemotherapy.|$|E
5000|$|Secondary {{lymphedema}} affects {{both men}} and women. In women, it is most prevalent in the upper limbs after breast cancer surgery, in particular after <b>axillary</b> <b>lymph</b> <b>node</b> dissection, occurring in the arm {{on the side of}} the body in which the surgery is performed. Breast and trunk lymphedema can also occur but, go unrecognised as there is swelling in the area after surgery and its symptoms ( [...] peau d' orange and/or an inverted nipple [...] ) can be confused with post surgery fat necrosis. In Western countries, secondary lymphedema is most commonly due to cancer treatment. Between 38 and 89% of breast cancer patients suffer from lymphedema due to <b>axillary</b> <b>lymph</b> <b>node</b> dissection and/or radiation. Unilateral lymphedema occurs in up to 41% of patients after gynecologic cancer. For men, a 5-66% incidence of lymphedema has been reported in patients treated with incidence depending on whether staging or radical removal of lymph glands was done in addition to radiotherapy.|$|E
5000|$|... #Caption: The {{children}} {{showing the}} location of the scar where the <b>axillary</b> <b>lymph</b> <b>nodes</b> were excised.|$|R
5000|$|... #Caption: Snowball like hyperechogenic <b>axillary</b> <b>lymph</b> <b>nodes</b> in a {{woman with}} {{silicone}} implants removed due to complications.|$|R
50|$|In IIIA {{there is}} breast cancer with <b>axillary</b> <b>lymph</b> <b>nodes</b> clumped {{together}} or attached to other structures.|$|R
50|$|Mutations in {{the human}} WISP3 gene are {{associated}} with progressive pseudorheumatoid dysplasia, a juvenile onset autosomal recessive skeletal disorder, indicating that the gene is essential for normal postnatal skeletal growth and cartilage homeostasis. However, mice with WISP3 knockout or overexpression are normal and suffer no apparent developmental defect. Loss of WISP3 expression is associated with aggressive inflammatory breast cancer and breast cancer with <b>axillary</b> <b>lymph</b> <b>node</b> metastasis, suggesting that WISP3/CCN6 may function as a suppressor of breast cancer growth and metastasis.|$|E
50|$|CUP is a {{term that}} refers to many {{different}} cancers. For that reason, treatment depends on where the cancer is found, the microscopic appearance of the cancer cells, the biochemical characterization of the cells, and the patient’s age and overall physical condition. In women, who present with <b>axillary</b> <b>lymph</b> <b>node</b> involvement, treatment is offered {{along the lines of}} breast cancer. In patients, who have neck lymph node involvement, then treatment is offered along the lines of head and neck cancer. If inguinal lymph nodes are involved, then treatment may be offered along the lines of genitourinary cancer.|$|E
50|$|Most studies {{investigating}} the effects exercise {{in patients with}} lymphedema or at risk of developing lymphedema examined patients with breast-cancer-related lymphedema. In these studies, resistance training did not increase swelling in patients with pre-existing lymphedema and decreases edema in some patients, {{in addition to other}} potential beneficial effects on cardiovascular health. Moreover, resistance training and other forms of exercise were not associated with an increased risk of developing lymphedema in patients who previously received breast cancer-related treatment. Compression garments should be worn during exercise (with the possible exception of swimming in some patients). Patients who have or risk lymphedema should consult their physician or certified lymphedema therapist before beginning an exercise regimen. Resistance training is not recommended in the immediate post-operative period in patients who have undergone <b>axillary</b> <b>lymph</b> <b>node</b> dissection for breast cancer.|$|E
40|$|Objective: To {{assess the}} {{contribution}} of kinetic characteristics in the discrimination of malignant-benign <b>axillary</b> <b>lymph</b> <b>nodes.</b> Material and Methods: One hundred fifty-five female patients {{were included in the}} study. Following magnetic resonance imaging (MRI) examinations post-processing applications were applied, dynamic curves were obtained from subtracted images. Types of dynamic curves were correlated with histopathological results in malignant cases or final clinical results in patients with no evidence of malignancy. Sensitivity, specificity, positive likehood ratio (+LHR), negative (-LHR) of dynamic curves characterizing the <b>axillary</b> <b>lymph</b> <b>nodes</b> were calculated. Results: A total of 178 <b>lymph</b> <b>nodes</b> greater than 8 mm were evaluated in 113 patients. Forty-six <b>lymph</b> <b>nodes</b> in 24 cases had malignant <b>axillary</b> involvement. 132 <b>lymph</b> <b>nodes</b> in 89 patients with benign diagnosis were included in the study. The sensitivity of type 3 curve as an indicator of malignancy was calculated as 89 %. However the specificity, +LHR, -LHR were calculated as 14 %, 1. 04, 0. 76 respectively. Conclusion: Since kinetic analysis of both benign and malignant <b>axillary</b> <b>lymph</b> <b>nodes,</b> rapid enhancement and washout (type 3) they cannot be used as a discriminator, unlike breast lesions. MRI, depending on the kinetic features of the <b>axillary</b> <b>lymph</b> <b>nodes,</b> is not high enough {{to be used in the}} clinical management of breast cancer patients...|$|R
5000|$|It {{has spread}} to 1 to 3 <b>axillary</b> <b>lymph</b> <b>nodes</b> (N1a), but not to distant sites (M0), or ...|$|R
2500|$|... 1773. Bernard Peyrilhe treated {{breast cancer}} by radical mastectomy which {{included}} both the pectoral muscle and <b>axillary</b> <b>lymph</b> <b>nodes.</b>|$|R
5000|$|The {{clinical}} presentation {{varies according to}} the type of ALCL. Two of the ALCL subtypes are systemic lymphomas, in that they usually present with enlarged lymph nodes in multiple regions of the body, or with tumors outside the lymph nodes (extranodal) such as bone, intestine, muscle, liver, or spleen. These 2 subtypes usually associate with weight loss, fevers and night sweats, and can be lethal if left untreated without chemotherapy. [...] The third type of ALCL is so-called cutaneous ALCL, and is a tumor that presents in the skin as ulcers that may persist, or occasionally may involute spontaneously, and commonly recur. This type of ALCL usually manifests in different regions of the body and may extend to regional lymph nodes, i.e., an <b>axillary</b> <b>lymph</b> <b>node</b> if the ALCL presents in the arm.|$|E
50|$|The {{taking of}} a medical history and exam by a medical {{practitioner}} can help point {{to the cause of}} the swelling, whether it be a localised infection, or a systemic disorder. Many symptoms or signs may point to the cause of swelling - for example, a sore throat and a cough may point to an upper respiratory tract infection as the cause of tonsil swelling. Changes in the appearance of a breast or a mass that has been felt may explain underarm pain and <b>axillary</b> <b>lymph</b> <b>node</b> swelling. Ongoing fevers or night sweats may suggest a systemic infection or a lymphoma as the cause of swelling. Depending on these findings, a wide variety of medical tests that include blood tests and scans may be needed to further examine the cause. A biopsy of a lymph node may also be needed.|$|E
5000|$|Breast hematoma {{due to an}} {{operation}} will normally resolve with time but should be followed up with more detailed evaluation if it does not. Breast abscess can occur as post-surgical complication, for example after cancer treatment or reduction mammaplasty. Furthermore, if a breast has already undergone irradiation (as in radiation therapy for treating breast cancer), there is a heightened risk of complications (e.g. reactive inflammation, occurrence of a chronic draining wound, etc.) for breast biopsies or other interventions to the breast, even those often considered [...] "minor" [...] surgeries. The combined effects of radiation and breast cancer surgery can in particular lead to complications such as breast fibrosis, secondary lymphedema (which may occur in the arm, the breast or the chest, in particular after <b>axillary</b> <b>lymph</b> <b>node</b> dissection), breast asymmetry, and chronic/recurrent breast cellulitis, each of these having long-term effects.|$|E
5000|$|... #Caption: 2. Axillary lymphatic plexus4. Cubital <b>lymph</b> <b>nodes</b> (not {{part of the}} <b>lymph</b> <b>node</b> {{drainage}} of the breast)5. Superficial axillary (low axillary)6. Deep <b>axillary</b> <b>lymph</b> nodes7. Brachial <b>axillary</b> <b>lymph</b> nodes8. Interpectoral <b>axillary</b> <b>lymph</b> <b>nodes</b> (Rotter nodes)10. Paramammary or intramammary lymph nodes11. Parasternal <b>lymph</b> <b>nodes</b> (internal mammary nodes) ...|$|R
40|$|International audienceMetaplastic breast {{carcinoma}} with fibromatosis-like {{pattern of}} growth is rare and recently described type of breast carcinoma. In a few studies it was demonstrated that these tumors have {{a high risk of}} local reccurence and that they may occasionally metastasize distantly but not to the <b>axillary</b> <b>lymph</b> <b>nodes.</b> We report a case of fibromatosis-like metaplastic carcinoma with unusual morphology that progressively changed in several reccurences and metastasized to <b>axillary</b> <b>lymph</b> <b>nodes</b> and also distantly...|$|R
40|$|Aim: The aim of {{the study}} was to {{identify}} factors that influence the positivity on axillar status at patients with early breast cancer with clinical negative axilla, at which were done radical surgery to breast but also radical lymphadenectomy of axillar <b>lymph</b> <b>nodes.</b> Material and methods: In the study were included 81 surgically treated patients with early breast cancer during 08 - 2015 to 05 - 2017 year. All the cases have been analyzed by standard histological analysis including macroscopic and microscopic analysis on standard H&E staining. For determining of molecular receptors immunostaining by PT LINK immunoperoxidase has been done for HER 2 neu, ER, PR, p 53 and Ki 67.     Results: Patients age ranged between 31 - 73 years, average of 56. 86 years. The mean size of the primary tumor in the surgically treated patient was 20. 33 + 6. 0 mm. On dissection from the axilary pits there were taken out 5 to 32 <b>lymph</b> <b>nodes,</b> an average of 14. Metastases have been found in 1 to 7 <b>lymph</b> <b>nodes,</b> an average 0. 7. In only 26 (32. 1 %) of the patients have been found metastases in the <b>axillary</b> <b>lymph</b> <b>nodes.</b> The univariant regression analysis showed that the size of tumor and presence of HER 2 neu receptors on cancer cell influence on the positivity of the <b>axillary</b> <b>lymph</b> <b>nodes.</b> The presence of the estrogen receptors, progesterone receptors  showed that they do not have influence on the positivity for metastatic deposits in <b>axillary</b> <b>lymph</b> <b>nodes.</b> Multivariant model and logistic regression analysis as independent significant factors or predictors of positivity of the <b>axillary</b> <b>lymph</b> <b>nodes</b> is influenced from the tumor size only. Conclusion: Our study showed that the involving of the <b>axillary</b> <b>lymph</b> <b>nodes</b> is mainly influenced from the size of the tumor and presence of HER 2 neu receptors  in the univariant analysis points the important influence of positivity in the <b>axillary</b> <b>lymph</b> <b>nodes</b> but only size of the tumor in multivariate regressive analysis...|$|R
5000|$|Simple mastectomy (or [...] "total mastectomy"): In this procedure, {{the entire}} breast tissue is removed, but {{axillary}} contents are undisturbed. Sometimes the [...] "sentinel lymph node"—that is, the first <b>axillary</b> <b>lymph</b> <b>node</b> that the metastasizing cancer cells {{would be expected}} to drain into—is removed. People who undergo a simple mastectomy can usually leave the hospital after a brief stay. Frequently, a drainage tube is inserted during surgery in their chest and attached to a small suction device to remove subcutaneous fluid. These are usually removed several days after surgery as drainage decrease to less than 20-30 ml per day. People that {{are more likely to have}} the procedure of a simple or total mastectomy are those that have large areas of ductal carcinoma in situ or even those persons that are removing the breast because of the possibility of breast cancer occurring in the future (prophylactic mastectomies). When this procedure is done on a cancerous breast, it is sometimes also done on the healthy breast to forestall the appearance of cancer there. The choice of this [...] "contralateral prophylactic" [...] option has become more typical in recent years in California, most notable in people younger than 40, climbing from just 4 percent to 33 percent from 1998 to 2011. However, the possible benefits appear to be marginal at best in the absence of genetic indicators, according to a large-scale study published in 2014. [...] For healthy people known to be at high risk for breast cancer, this surgery is sometimes done bilaterally (on both breasts) as a cancer-preventive measure.|$|E
40|$|Abstract Background:Lymph node {{metastasis}} is {{the most}} important prognostic factor in breast cancer patients. The present study was carried out to evaluate the association between ER, PR and HER- 2 /neu expression status, separately and in combinations with <b>axillary</b> <b>lymph</b> <b>node</b> involvement. Patients and methods: Two hundred and fifty eight breast cancer patients treated with modified radical mastectomy with <b>axillary</b> <b>lymph</b> <b>node</b> dissection were included. The primary tumor tissue and <b>axillary</b> <b>lymph</b> <b>node</b> were evaluated histologically and the expression of ER, PR and HER- 2 /neu was evaluated by immune his to chemistry. Results: ER and PR expression were demonstrated in 78. 7 % and 76. 4 %, respectively and over-expression of HER- 2 /neu was detected in 13. 2 % of cases. Triple positive breast cancer is more likely to have <b>axillary</b> <b>lymph</b> <b>node</b> metastasis and ER+/PR+/HER- 2 - (PPN) {{is the most}} protected group (p<= 0. 001). There was a strong correlation between tumor size and tumor grade with lymph node involvement (p = 0. 0001 and 0. 024, respectively). Conclusion: triple positive breast carcinomas are more likely <b>axillary</b> <b>lymph</b> <b>node</b> metastasis. Tumor size, tumor grade and pathological subtypes correlate with <b>axillary</b> <b>lymph</b> <b>node</b> status. Further confirmatory studies with a larger number of patients are necessary to define factors predicting <b>axillary</b> <b>lymph</b> <b>node</b> status...|$|E
40|$|BACKGROUND: If {{treatment}} of the axilla is indicated in patients with breast cancer who have a positive sentinel node, <b>axillary</b> <b>lymph</b> <b>node</b> dissection is the present standard. Although <b>axillary</b> <b>lymph</b> <b>node</b> dissection provides excellent regional control, it is associated with harmful side-effects. We aimed to assess whether axillary radiotherapy provides comparable regional control with fewer side-effects. METHODS: Patients with T 1 - 2 primary breast cancer and no palpable lymphadenopathy {{were enrolled in the}} randomised, multicentre, open-label, phase 3 non-inferiority EORTC 10981 - 22023 AMAROS trial. Patients were randomly assigned (1 : 1) by a computer-generated allocation schedule to receive either <b>axillary</b> <b>lymph</b> <b>node</b> dissection or axillary radiotherapy in case of a positive sentinel node, stratified by institution. The primary endpoint was non-inferiority of 5 -year axillary recurrence, considered to be not more than 4 % for the axillary radiotherapy group compared with an expected 2 % in the <b>axillary</b> <b>lymph</b> <b>node</b> dissection group. Analyses were by intention to treat and per protocol. The AMAROS trial is registered with ClinicalTrials. gov, number NCT 00014612. FINDINGS: Between Feb 19, 2001, and April 29, 2010, 4823 patients were enrolled at 34 centres from nine European countries, of whom 4806 were eligible for randomisation. 2402 patients were randomly assigned to receive <b>axillary</b> <b>lymph</b> <b>node</b> dissection and 2404 to receive axillary radiotherapy. Of the 1425 patients with a positive sentinel node, 744 had been randomly assigned to <b>axillary</b> <b>lymph</b> <b>node</b> dissection and 681 to axillary radiotherapy; these patients constituted the intention-to-treat population. Median follow-up was 6. 1 years (IQR 4. 1 - 8. 0) for the patients with positive sentinel lymph nodes. In the <b>axillary</b> <b>lymph</b> <b>node</b> dissection group, 220 (33 %) of 672 patients who underwent <b>axillary</b> <b>lymph</b> <b>node</b> dissection had additional positive nodes. Axillary recurrence occurred in four of 744 patients in the <b>axillary</b> <b>lymph</b> <b>node</b> dissection group and seven of 681 in the axillary radiotherapy group. 5 -year axillary recurrence was 0. 43 % (95 % CI 0. 00 - 0. 92) after <b>axillary</b> <b>lymph</b> <b>node</b> dissection versus 1. 19 % (0. 31 - 2. 08) after axillary radiotherapy. The planned non-inferiority test was underpowered because of the low number of events. The one-sided 95 % CI for the underpowered non-inferiority test on the hazard ratio was 0. 00 - 5. 27, with a non-inferiority margin of 2. Lymphoedema in the ipsilateral arm was noted significantly more often after <b>axillary</b> <b>lymph</b> <b>node</b> dissection than after axillary radiotherapy at 1 year, 3 years, and 5 years. INTERPRETATION: <b>Axillary</b> <b>lymph</b> <b>node</b> dissection and axillary radiotherapy after a positive sentinel node provide excellent and comparable axillary control for patients with T 1 - 2 primary breast cancer and no palpable lymphadenopathy. Axillary radiotherapy results in significantly less morbidity. FUNDING: EORTC Charitable Trust...|$|E
50|$|The <b>axillary</b> <b>lymph</b> <b>nodes</b> or armpit <b>lymph</b> <b>nodes</b> (20 to 49 in number) drain lymph vessels {{from the}} lateral {{quadrants}} of the breast, the superficial lymph vessels from thin {{walls of the}} chest and the abdomen above {{the level of the}} navel, and the vessels from the upper limb. They are divided in several groups according to their location in the armpit. These <b>lymph</b> <b>nodes</b> are clinically significant in breast cancer, and metastases from the breast to the <b>axillary</b> <b>lymph</b> <b>nodes</b> are considered in the staging of the disease.|$|R
30|$|US-guided core biopsy of {{suspicious}} <b>axillary</b> <b>lymph</b> <b>nodes</b> {{in patients}} with breast cancer allows for identification of metastatic nodes preoperatively [38, 39].|$|R
3000|$|... {{changes in}} <b>axillary</b> <b>lymph</b> <b>nodes.</b> As the mediastinal LNs are the lung-draining LNs, these LNs had the {{greatest}} increase in K [...]...|$|R
